Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
HELP · Why this verdict
Why Cybin (HELP) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.3/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
HELP fails the engine's quality floor (1.2 vs. 4.0) on negative FCF and a weak Piotroski score, and its analyst target was flagged as implausible and rejected — consistent with the exit-position action note — while an overbought technical bounce and a binary earnings report in 12 days add near-term event risk.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The engine flagged the raw analyst price target of $37.55 as implausible against the current price of $7.62, a 4.9x ratio, and rejected it in favor of a technical take-profit level, indicating unreliable analyst coverage for this name. Warnings | As coverage normalizes, a resolved analyst target should fall within a plausible range, roughly 1-2x current price, rather than requiring rejection. | ↓Deteriorating |
| CounterThis may reflect a stale or erroneous data feed rather than a genuine problem with analyst estimates, and could resolve on the next data refresh without changing the underlying investment case. | ||
Quality sits well below the engine's floor, 1.2 vs. 4.0, driven by negative free cash flow and a weak Piotroski F-score of 2/9. Quality breakdown | For the exit thesis to be wrong, FCF should turn positive and the Piotroski score should climb to at least 4/9 within the next few quarters. | →Stable |
| CounterPre-revenue or early clinical-stage biotech companies routinely run negative FCF and score poorly on Piotroski by design, since the metric wasn't built for binary drug-development names. | ||
Shares are overbought at RSI 73 with rising on-balance volume in what the engine labels a recovery setup, a death cross that occurred previously but with improving MACD. Momentum breakdown | RSI should cool toward a neutral 50-60 range without a sharp price decline, confirming a genuine rather than exhausted recovery. | ↓Deteriorating |
| CounterRSI at 73 combined with a flat 200-day MA slope suggests the recovery could be a short-lived bounce within a longer downtrend rather than a durable trend change. | ||
The company has missed estimates in 3 of the last 4 quarters, with an average surprise of -14.5%, and faces its next report in 12 days, a binary catalyst given the earnings-concerns flag and speculative suitability classification. Catalyst breakdown | The company should beat or meet consensus at the upcoming report to break the recent pattern of misses. | →Stable |
| CounterAs a speculative biotech, near-term financial results may be less relevant to price action than clinical-trial or regulatory catalysts not captured in this data. | ||
The engine flagged the raw analyst price target of $37.55 as implausible against the current price of $7.62, a 4.9x ratio, and rejected it in favor of a technical take-profit level, indicating unreliable analyst coverage for this name.
↓DeterioratingWarnings
- Expectation
- As coverage normalizes, a resolved analyst target should fall within a plausible range, roughly 1-2x current price, rather than requiring rejection.
CounterThis may reflect a stale or erroneous data feed rather than a genuine problem with analyst estimates, and could resolve on the next data refresh without changing the underlying investment case.
Quality sits well below the engine's floor, 1.2 vs. 4.0, driven by negative free cash flow and a weak Piotroski F-score of 2/9.
→StableQuality breakdown
- Expectation
- For the exit thesis to be wrong, FCF should turn positive and the Piotroski score should climb to at least 4/9 within the next few quarters.
CounterPre-revenue or early clinical-stage biotech companies routinely run negative FCF and score poorly on Piotroski by design, since the metric wasn't built for binary drug-development names.
Shares are overbought at RSI 73 with rising on-balance volume in what the engine labels a recovery setup, a death cross that occurred previously but with improving MACD.
↓DeterioratingMomentum breakdown
- Expectation
- RSI should cool toward a neutral 50-60 range without a sharp price decline, confirming a genuine rather than exhausted recovery.
CounterRSI at 73 combined with a flat 200-day MA slope suggests the recovery could be a short-lived bounce within a longer downtrend rather than a durable trend change.
The company has missed estimates in 3 of the last 4 quarters, with an average surprise of -14.5%, and faces its next report in 12 days, a binary catalyst given the earnings-concerns flag and speculative suitability classification.
→StableCatalyst breakdown
- Expectation
- The company should beat or meet consensus at the upcoming report to break the recent pattern of misses.
CounterAs a speculative biotech, near-term financial results may be less relevant to price action than clinical-trial or regulatory catalysts not captured in this data.
Per-dimension breakdown
Quality
1.2/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 3.8 |
| Piotroski F | 2.2 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 2/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
7.1/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.2 |
| MACD | 8.7 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 3.4 |
- ▸Overbought (RSI 77)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
8.1/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.4 |
| Analyst rating | 8.0 |
| Price target | 10.0 |
- ▸Light analyst coverage (9.0) — signal dampened
- ▸Analyst upside: 187%
Insider
5.0/10data confidence 50%Peer rank
4.0/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 1.0 |
| growth rank | 5.0 |
Technical
4.1/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.5 |
| support resistance | 0.4 |
| 52w position | 9.6 |
| gap | 5.0 |
Risk (lower is worse)
5.3/10data confidence 100%| Component | Sub-score |
|---|---|
| days to cover | 8.9 |
| volatility | 0.0 |
| put call | 6.1 |
| implied vol | 0.0 |
| max pain risk | 7.0 |
| beta | 9.6 |
- ▸High IV: 97%
Catalyst
3.2/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
| news activity | 6.0 |
- ▸Earnings concerns: 1B/3M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (7)
- MOMENTUM:7.1>=5.5
- ASYMMETRY:9.9>=1.5
- INSIDER:OK
- 8K:CLEAN
- EARNINGS_PROXIMITY:83d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (0)
none
Reward-to-Risk
9.95
Upside
+149.3%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($0.9B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects clean gate clearance against Value at 9.0 and asymmetric R:R of 9.95.
The strongest dimensions are Value at 9.0, Sentiment at 8.1, and Momentum at 7.1; the weakest are Quality at 1.2, Catalyst at 3.2, and Peer rank at 4.0. The V9 engine cleared all gates, producing an asymmetric reward-to-risk of 9.95 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Implausible Analyst Target Flag
Trip ifThe analyst-target data-quality flag persists for more than 3 consecutive refreshes without resolving to a plausible, sub-2x, ratio, confirming a structural data-coverage problem.
- P2Cash Burn Quality Floor Breach
Trip ifPiotroski F-Score rises above 4 out of 9 and FCF turns positive at the next fundamental refresh, contradicting the current quality-floor breach.
- P3Overbought Recovery Bounce
Trip ifPrice falls more than 15% from current levels within 6 weeks of the overbought reading, showing the recovery was a short-lived bounce rather than a genuine trend change.
- P4Binary Earnings Catalyst
Trip ifThe company misses consensus estimates by more than 20% at the next report, extending the current 3-of-4 miss streak.